Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01907113|
Recruitment Status : Completed
First Posted : July 24, 2013
Results First Posted : July 14, 2014
Last Update Posted : July 14, 2014
|Study Design||Allocation: Non-Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment|
Diabetes Mellitus, Type 2
Drug: BI 10773
The trial was conducted in two trial centres as an open-label, parallel group design with one treatment period.
The trial was performed in 40 male and female patients who were assigned to five treatment groups according to their creatinine clearance.